FST and metabolic dysfunction-associated steatotic liver disease: A possible mechanism may involve an effect of follistatin to induce adipose tissue insulin resistance, resulting in increased adipocyte free fatty acid (FFA) release, which also promotes nonalcoholic fatty liver disease (NAFLD).